Dr. Maria Teresa Landi

Dr. Maria Teresa Landi

Senior Investigator, Integrative Tumor Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA

Dr. Landi is an M.D., Ph.D. with training in clinical oncology and molecular epidemiology and tenured Senior investigator at the National Cancer Institute, NIH.

She has focused her research on the environmental and genetic determinants of lung cancer and melanoma, and more recently on the genomic landscape of these tumors.

In lung cancer, she is currently leading two large population-based studies and uses next-generation sequencing and genome-wide analyses to explore lung cancer etiology and clonal evolution.

In her melanoma research, she investigates the relationship of UV radiation, genetic susceptibility and other host factors in population studies and in melanoma-prone families.

 
ABSTRACT

Title: Sherlock-Lung: Tracing lung cancer mutational processes in never smokers

Summary: Lung cancer in never smokers includes approximately 10-25% of all lung cancers worldwide, ranks among the most common causes of cancer mortality, and has a distinct natural history, restricted histological subtype (almost exclusively adenocarcinoma), different profile of oncogenic mutations, and response to targeted therapy compared to lung cancer in smokers.

Although few risk factors are known to contribute to the etiology of lung cancer in never smokers, a large fraction of cancer cases cannot be explained by established environmental and genetic risk factors, highlighting the need for research in this area.

One promising approach to identify the etiological factors involved in lung tumorigenesis in never smokers is based on the study of the “mutational signatures” that the exogeneous and endogenous processes leave on the tumor tissue and surrounding areas. I will describe the Sherlock-Lung study that was designed at the National Cancer Institute, NIH to implement this approach.

I will present preliminary results and possibilities for collaboration.

IACR Charity Funding

The IACR is a charity which needs your help to support early-stage oncology scientific researchers

What's On? IACR 2023 Agenda

Download the initial draft of the IACR BioMedical agenda for our 59th Annual Conference.

Registration/ Membership for IACR 2023

Registration for the 59th Annual Conference in the Radisson Blu hotel, Athlone is Now Open.

EACR Membership is Included

The IACR is an affiliated national society and its members benefit from full membership of the EACR.

Late Breaking Abstracts in Now OPEN!

Biomedical Session Abstracts

Deadline: Midnight, Friday, 20th January 2023

Please note:
- Patrick Johnston Lay submission category is now closed
- Late Breaking Abstracts submitted to the Biomedical Sessions will be considered for Display Poster Presentation. 

Social Nursing and Allied Health (SNAH) Abstracts

Deadline: Midnight, Monday, 9th January 2023

SNAH abstract submissions will remain open until Monday 9th January.

Any questions?
Please contact Sinead on: sinead@sineadcassidy.com

Contact Us

10 + 11 =

Contact Us
Irish Association for Cancer Research
9A Coolkill, Sandyford, Dublin 18

T: +353 (0)1 295 8859
E: info@iacr.ie

Irish Association for Cancer Research (IACR) is a registered charity on the Register of Charitable Organisations.

Registered Charity Number (RCN): 20030117

Design by patterns.ie
© 2022